Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income: 2019-2025

Historic Net Income for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to -$1.9 million.

  • Eton Pharmaceuticals' Net Income fell 407.34% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 21.91%. This contributed to the annual value of -$3.8 million for FY2024, which is 308.44% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Net Income stood at -$1.9 million, which was up 25.45% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Net Income peaked at $5.1 million during Q1 2021, and registered a low of -$6.1 million during Q3 2021.
  • In the last 3 years, Eton Pharmaceuticals' Net Income had a median value of -$1.6 million in 2025 and averaged -$985,727.
  • In the last 5 years, Eton Pharmaceuticals' Net Income surged by 392.62% in 2023 and then tumbled by 407.34% in 2025.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Net Income stood at $1.0 million in 2021, then declined by 12.22% to $912,000 in 2022, then crashed by 347.37% to -$2.3 million in 2023, then surged by 73.49% to -$598,000 in 2024, then slumped by 407.34% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$2.6 million for Q2 2025, and -$1.6 million during Q1 2025.